Model COVID

Cluet David

04/03/2022

Experimental setup

Table 1: Linear treshold used to binarize the channels

	IFN-Lambda	CD83	PD-L1	IFNa	CD80
Cohorte 1	4200	9900	574	437	574
Cohorte 2	4100	10000	1200	482	528
Cohorte 3	2600	11000	5200	579	623
Cohorte 4	2100	5200	1200	447	464
Cohorte 5	3100	5200	1200	623	623
Cohorte 6	2100	5200	388	447	667
Pilote 1	10000	2200	652	479	256
Pilote 2	2600	10000	2200	535	623




Figure 1: Experimental thresholds

IFN1	CD83	PDL1	IFNa
Min. :0.000	Min. :0.00000	Min. :0.0000	Min. :0.00000
1st Qu.:0.000	1st Qu.:0.00000	1st Qu.:0.0000	1st Qu.:0.00000
Median :0.000	Median :0.00000	Median :0.0000	Median :0.00000
Mean :0.102	Mean :0.07435	Mean :0.2532	Mean :0.01763
3rd Qu.:0.000	3rd Qu.:0.00000	3rd Qu.:1.0000	3rd Qu.:0.00000
Max. :1.000	Max. :1.00000	Max. :1.0000	Max. :1.00000
CD80	Patient	Cohorte	Activation
Min. :0.00000	Length:219346	Length:219346	6 Length:219346
1st Qu.:0.00000	Class :characte	r Class :charac	cter Class :character
Median :0.00000	Mode :characte	r Mode :charac	cter Mode :character
Mean :0.06908	1		
3rd Qu.:0.00000	1		
Max. :1.00000	1		
Severity	Status	perc_pDCs	
Min. :0.0000	Length:219346	Min. : 0.700)
1st Qu.:0.0000	Class :character	1st Qu.: 4.150)
Median :0.0000	Mode :character	Median : 7.730)
Mean :0.5773		Mean : 8.254	ŀ
3rd Qu.:1.0000		3rd Qu.:10.700)
Max. :2.0000		Max. :28.000)

	Patient	Cohorte	Status	Activation	pDCs	nCells	IFNl	CD83	PDL1	IFNa	CD80
27	AS-0030_pDC_A1	Cohorte 4	mild	Mock	7.75	441	13.83	4.99	1.13	0.23	1.30
41	$AS-0030_pDC_A2$	Cohorte 4	mild	SARS	22.20	1016	37.80	46.75	16.63	32.09	0.79
25	$AS-0030_pDC_A3$	Cohorte 4	mild	Agonist	13.10	743	55.32	17.63	48.86	0.81	4.7
67	$AS-0030_pDC_B1$	Cohorte 4	mild	Mock	5.39	237	19.41	1.69	0.84	0.42	2.9
81	$AS-0030_pDC_B2$	Cohorte 4	mild	SARS	9.07	381	10.76	6.56	2.10	2.89	3.4
109	$AS-0030_pDC_B3$	Cohorte 4	mild	Agonist	14.90	585	65.98	10.60	40.68	0.51	24.65
101	$AS-0030_pDC_C1$	Cohorte 4	mild	Mock	7.69	98	10.20	10.20	3.06	3.06	10.20
20	$AS-0030_pDC_C2$	Cohorte 4	mild	SARS	14.20	120	20.83	6.67	3.33	2.50	6.6'
68	$AS-0030_pDC_D1$	Cohorte 4	mild	Mock	11.70	526	3.42	0.76	2.47	0.19	4.94
63	$AS-0030_pDC_D2$	Cohorte 4	mild	SARS	25.60	1399	28.59	14.80	0.93	11.29	0.7
47	$AS-0030_pDC_D3$	Cohorte 4	mild	Agonist	14.70	1062	14.78	9.98	39.92	0.19	9.89
115	$AS-0030_pDC_E1$	Cohorte 4	mild	Mock	5.70	939	13.10	2.56	6.60	0.32	8.5
82	$AS-0030_pDC_E2$	Cohorte 4	mild	SARS	8.42	917	9.71	5.23	6.11	1.96	8.63
126	$AS-0030_pDC_E3$	Cohorte 4	mild	Agonist	8.95	1632	24.02	9.99	29.96	0.06	6.19
116	BC_HV2_pDC_I1	Cohorte 2	healthy	Mock	3.40	1045	1.63	3.92	10.72	0.77	11.20
19	BC_HV2_pDC_I2	Cohorte 2	healthy	SARS	5.84	1846	3.68	5.96	4.28	6.23	3.1_{-}
107	BC_HV2_pDC_I3	Cohorte 2	healthy	Agonist	4.66	2009	0.45	8.01	92.83	0.25	7.5'
85	BRU_Chr_pDC_F1	Cohorte 2	severe	Mock	1.62	147	4.76	4.08	3.40	2.04	7.48
100	$BRU_Chr_pDC_F2$	Cohorte 2	severe	SARS	1.26	184	1.63	0.54	13.04	5.43	15.25
30	BRU_Chr_pDC_F3	Cohorte 2	severe	Agonist	0.88	341	0.59	3.81	12.90	1.47	6.10
36	BV_HV1_pDC_J1	Cohorte 3	healthy	Mock	9.24	9819	0.32	2.12	1.18	0.15	5.18
108	$BV_HV1_pDC_J2$	Cohorte 3	healthy	SARS	10.40	12635	51.82	2.19	0.86	0.66	4.84
127	BV_HV1_pDC_J3	Cohorte 3	healthy	Agonist	10.70	11477	34.50	3.13	27.89	0.17	3.1
56	CHA_Mah_pDC_F1	Cohorte 1	severe	Mock	2.78	3523	4.85	1.73	14.33	0.11	14.22
62	$CHA_Mah_pDC_F2$	Cohorte 1	severe	SARS	4.32	3394	0.53	2.30	13.82	0.27	14.29
64	CHA_Mah_pDC_F3	Cohorte 1	severe	Agonist	2.99	2426	8.45	10.84	35.20	0.91	9.2'
76	EFS_P1_0901_pDC_3	Pilote 1	healthy	Mock	8.14	987	8.31	12.97	4.36	0.00	4.70
98	EFS_P1_0901_pDC_4	Pilote 1	healthy	SARS	9.61	775	1.68	8.77	3.35	2.32	2.9'
34	EFS_P1_0901_pDC_5	Pilote 1	healthy	Agonist	8.73	1184	1.86	54.90	92.74	0.17	7.18
111	EFS_P1_0930_pDC_6	Pilote 1	healthy	Mock	16.20	932	3.00	3.76	2.25	0.00	2.4'

	Patient	Cohorte	Status	Activation	pDCs	nCells	IFNl	CD83	PDL1	IFNa	CD80
103	EFS_P1_0930_pDC_7	Pilote 1	healthy	SARS	15.80	1117	9.76	20.32	7.25	14.68	2.1
7	EFS_P1_0930_pDC_8	Pilote 1	healthy	Agonist	7.65	1011	1.09	46.39	95.55	0.79	25.55
106	EFS_P2_0901_pDC_4	Pilote 2	healthy	SARS	9.03	203	3.45	13.30	1.97	9.36	1.9'
73	EFS P2 1112 pDC 8	Pilote 2	healthy	Mock	25.70	652	0.31	1.38	26.84	0.46	3.68
53	EFS_P2_1112_pDC_9	Pilote 2	healthy	SARS	28.00	814	2.70	11.06	39.56	6.51	2.58
132	GC-0017_pDC_A1	Cohorte 3	mild	Mock	3.09	307	0.33	3.26	0.00	0.33	3.9
96	GC-0017_pDC_A2	Cohorte 3	mild	SARS	3.25	316	3.80	6.96	0.63	2.22	6.3
78	GC-0017_pDC_A3	Cohorte 3	mild	Agonist	5.38	630	10.95	5.08	6.98	1.75	14.29
99	GC-0017_pDC_B1	Cohorte 3	mild	Mock	1.66	179	0.00	5.03	0.56	1.68	5.59
21	GC-0017_pDC_B2	Cohorte 3	mild	SARS	2.17	262	0.38	4.58	0.38	2.67	8.0
125	GC-0017_pDC_B3	Cohorte 3	mild	Agonist	1.80	323	0.31	3.10	2.48	2.79	15.48
2	GC-0017_pDC_C1	Cohorte 3	mild	Mock	2.87	292	0.00	4.45	0.00	2.40	5.85
3	GC-0017_pDC_C2	Cohorte 3	mild	SARS	4.16	633	0.16	4.27	1.26	2.05	6.64
66	GC-0017 pDC C3	Cohorte 3	mild	Agonist	5.28	968	0.72	8.57	24.07	0.93	8.68
136	GC-0017_pDC_E1	Cohorte 3	mild	Mock	3.86	1612	0.50	5.09	0.87	1.05	7.5'
14	GC-0017_pDC_E2	Cohorte 3	mild	SARS	4.50	2201	0.14	3.09	0.27	0.45	5.48
71	GC-0017_pDC_E3	Cohorte 3	mild	Agonist	4.25	3229	2.14	2.88	9.97	0.37	4.2
137	$GC-0038_pDC_A1$	Cohorte 2	mild	Mock	2.28	441	9.30	17.01	7.48	1.81	9.30
72	$GC-0038_pDC_A2$	Cohorte 2	mild	SARS	2.96	428	6.54	15.89	6.78	3.04	5.84
8	$GC-0038_pDC_A3$	Cohorte 2	mild	Agonist	2.29	552	4.35	4.53	23.19	0.36	7.79
28	GC-0038_pDC_B1	Cohorte 2	mild	Mock	3.84	458	1.97	11.57	5.90	1.75	8.73
4	$GC-0038_pDC_B2$	Cohorte 2	mild	SARS	5.32	648	2.16	16.36	5.09	6.48	5.7
123	$GC-0038_pDC_B3$	Cohorte 2	mild	Agonist	5.54	718	20.19	10.58	60.03	0.42	16.5'
122	$GC-0038_pDC_C1$	Cohorte 2	mild	Mock	6.34	819	1.71	7.20	5.86	0.37	7.8
35	$GC-0038_pDC_C2$	Cohorte 2	mild	SARS	8.07	1240	1.37	8.87	9.52	4.60	5.68
121	$GC-0038_pDC_C3$	Cohorte 2	mild	Agonist	4.92	1353	32.67	14.63	61.35	0.44	10.42
129	$GC-0038_pDC_D1$	Cohorte 2	mild	Mock	6.93	962	0.62	6.55	5.30	0.31	6.24
58	$GC-0038_pDC_D2$	Cohorte 2	mild	SARS	6.54	1185	3.97	12.15	8.35	7.26	5.83
49	$GC-0038_pDC_D3$	Cohorte 2	mild	Agonist	6.98	1235	1.13	11.66	72.31	0.49	8.9
104	HD_3M31_pDC_K1	Cohorte 5	healthy	Mock	6.23	1268	0.08	4.34	8.60	0.39	7.10
9	HD_3M31_pDC_K2	Cohorte 5	healthy	SARS	9.78	1504	0.33	8.78	13.83	0.53	12.70
133	HD_3M31_pDC_K3	Cohorte 5	healthy	Agonist	5.66	1701	1.65	20.75	60.08	0.76	7.23
119	HD_6M20_pDC_H1	Cohorte 1	healthy	Mock	11.40	1428	1.19	3.71	7.35	0.84	7.98
69	HD_6M20_pDC_H2	Cohorte 1	healthy	SARS	13.80	1524	1.12	5.45	6.82	0.85	7.48
51	HD_6M20_pDC_H3	Cohorte 1	healthy	Agonist	13.60	1494	2.28	4.69	68.34	0.74	7.90
113	HD_EF9S_pDC_K1	Cohorte 6	healthy	Mock	4.25	3691	1.87	2.33	27.85	1.00	17.20
112	HD_EF9S_pDC_K2	Cohorte 6	healthy	SARS	6.43	4386	2.37	4.56	20.95	1.14	9.69
131	HD_EF9S_pDC_K3	Cohorte 6	healthy	Agonist	4.15	3401	0.53	15.29	56.34	2.41	9.03
93	HOU_ED_pDC_F1	Cohorte 3	severe	Mock	1.60	1812	1.05	2.10	0.00	1.16	5.68
120	HOU_ED_pDC_F2	Cohorte 3	severe	SARS	1.52	2065	1.21	2.18	0.34	1.31	6.30
59	HOU_ED_pDC_F3	Cohorte 3	severe	Agonist	2.87	3466	2.34	3.92	31.07	0.61	3.64
32	HOU_ED_pDC_G1	Cohorte 3	severe	Mock	1.47	1731	0.46	0.92	0.23	0.46	9.5
135	HOU_ED_pDC_G2	Cohorte 3	severe	SARS	1.29	2530	3.24	0.47	0.71	0.95	14.7
37	HOU_ED_pDC_G3	Cohorte 3	severe	Agonist	2.01	3150	1.87	2.13	26.25	0.70	3.50
44	HOU_ED_pDC_H1	Cohorte 3	severe	Mock	1.52	929	0.11	1.08	0.22	1.18	6.6
54 48	HOU_ED_pDC_H2	Cohorte 3	severe	SARS	0.78	662	0.00	1.06	0.45	0.45	7.5
$\frac{48}{124}$	HOU_ED_pDC_H3 HV_29_pDC_J1	Cohorte 3	severe	Agonist Mock	0.98	$1524 \\ 673$	1.90 1.63	2.69	$13.85 \\ 3.27$	1.18	4.40 4.90
$\frac{124}{42}$	HV_29_pDC_J1 HV_29_pDC_J2	Cohorte 4 Cohorte 4	healthy healthy	SARS	9.05	1338	18.16	1.78	$\frac{3.27}{2.09}$	$0.45 \\ 2.62$	4.904.04
$\frac{42}{24}$					9.66	2177		4.78			$\frac{4.04}{7.1}$
24 86	HV_29_pDC_J3	Cohorte 4 Cohorte 6	healthy	Agonist Mock	10.60	1002	35.42 7.29	11.85	50.80 17.66	0.18 2.99	
80 94	HV_F23_pDC_L1 HV_F23_pDC_L2	Cohorte 6	healthy healthy	SARS	$5.41 \\ 4.25$	850	0.71	$4.89 \\ 3.76$	17.00	2.99 2.94	11.18 8.15
94	11 v _ 1 23 _ pDC _ L2	Conorte 0	пеанну	SAILS	4.20	000	0.71	5.70	19.09	4.94	0.1.

	D. C. C.	G 1	- Cu i	A	D.C.	G 11	TENT	CD 00	DDI 1	TEN	CD 0
-	Patient	Cohorte	Status	Activation	pDCs	nCells	IFNl	CD83	PDL1	IFNa	CD8
39	Hu3_1_pDC_G1	Cohorte 1	healthy	Mock	13.50	5690	0.74	1.18	8.93	0.16	5.78
22	Hu3_1_pDC_G2	Cohorte 1	healthy	SARS	13.80	5443	0.51	3.55	10.80	3.69	2.30
105	Hu3_1_pDC_G3	Cohorte 1	healthy	Agonist	10.90	5046	0.57	4.00	80.60	0.40	3.3
40	Hu3_2_pDC_H1	Cohorte 2	healthy	Mock	15.70	3045	0.30	2.43	21.08	0.13	5.98
0	Hu3_2_pDC_H2	Cohorte 2	healthy	SARS	23.30	6617	5.27	10.40	34.65	12.44	1.45
29	Hu3_2_pDC_H3	Cohorte 2	healthy	Agonist	16.50	4383	0.23	5.45	85.65	0.27	5.00
57	Hu3_3_pDC_I1	Cohorte 3	healthy	Mock	0.99	766	0.26	4.31	0.78	2.22	12.40
17	Hu3_3_pDC_I2	Cohorte 3	healthy	SARS	1.36	1177	1.53	2.89	0.76	1.95	14.9
33	Hu3_3_pDC_I3	Cohorte 3	healthy	Agonist	2.78	1817	1.21	5.23	15.41	0.94	6.60
75	Hu3_4_pDC_I1	Cohorte 4	healthy	Mock	3.92	384	2.86	4.43	6.51	0.52	2.08
18	Hu3_4_pDC_I2	Cohorte 4	healthy	SARS	13.00	2469	36.49	12.72	9.72	4.58	1.0
61	Hu3_4_pDC_I3	Cohorte 4	healthy	Agonist	13.60	2995	56.13	18.46	72.25	0.17	6.58
83	Hu3_5_pDC_J1	Cohorte 5	healthy	Mock	7.88	1938	1.24	11.20	14.65	0.36	6.3
102	Hu3_5_pDC_J2	Cohorte 5	healthy	SARS	13.60	3028	0.83	7.46	11.20	2.44	2.4
88	Hu3_5_pDC_J3	Cohorte 5	healthy	Agonist	10.00	4357	13.38	20.95	79.64	0.11	4.1
90	LD-0175_pDC_A1	Cohorte 5	mild	Mock	1.01	287	0.35	14.98	10.10	4.18	13.2
134	LD-0175_pDC_A2	Cohorte 5	mild	SARS	0.74	381	0.00	15.75	6.30	1.84	9.4
92	LD-0175_pDC_A3	Cohorte 5	mild	Agonist	1.90	519	0.39	12.91	26.40	1.16	4.6
26	LD-0175_pDC_B1	Cohorte 5	mild	Mock	7.40	1390	0.14	10.29	6.33	0.22	6.1
23	LD-0175_pDC_B2	Cohorte 5	mild	SARS	10.90	1945	0.15	13.11	3.08	0.67	2.9
65	LD-0175_pDC_B3	Cohorte 5	mild	Agonist	7.73	2349	54.41	27.16	62.62	0.17	12.5
84	LD-0175_pDC_C1	Cohorte 5	mild	Mock	5.26	717	0.28	7.53	4.88	0.98	5.3
12	LD-0175_pDC_C2	Cohorte 5	mild	SARS	7.57	646	0.00	6.81	2.48	0.00	2.79
110	LD-0175_pDC_C3	Cohorte 5	mild	Agonist	5.46	1161	0.26	17.23	59.69	0.34	10.5
70	LD-0175_pDC_D1	Cohorte 5	mild	Mock	1.94	246	1.63	4.47	8.54	3.25	8.54
128	LD-0175_pDC_D2	Cohorte 5	mild	SARS	2.01	249	0.00	4.42	8.84	0.80	8.8
15	$LD-0175_pDC_D3$	Cohorte 5	mild	Agonist	3.48	658	0.91	19.76	55.62	0.61	8.3
5	OZBE_pDC_I1	Cohorte 5	severe	Mock	1.14	126	0.79	7.14	7.14	3.17	10.33
6	$OZBE_pDC_I2$	Cohorte 5	severe	SARS	1.15	110	0.91	2.73	10.00	1.82	10.0
118	PD-0041_pDC_A1	Cohorte 1	mild	Mock	1.17	945	0.74	5.50	8.25	1.69	9.5°
16	$PD-0041_pDC_A2$	Cohorte 1	mild	SARS	1.31	1002	0.50	8.78	6.99	0.80	9.08
77	PD-0041_pDC_A3	Cohorte 1	mild	Agonist	1.66	1154	1.99	3.38	10.31	0.95	5.75
79	PD-0041_pDC_B1	Cohorte 1	mild	Mock	2.80	662	33.99	10.73	7.70	2.57	8.0
11	$PD-0041_pDC_B2$	Cohorte 1	mild	SARS	2.72	695	0.00	7.34	7.19	0.14	6.19
114	PD-0041_pDC_B3	Cohorte 1	mild	Agonist	2.25	867	1.15	6.23	37.25	1.50	7.0-
38	PD-0041_pDC_C1	Cohorte 1	mild	Mock	3.07	485	0.82	0.62	9.69	1.65	11.7
45	$PD-0041_pDC_C2$	Cohorte 1	mild	SARS	3.84	610	0.00	5.90	5.90	0.82	6.39
13	PD-0041_pDC_C3	Cohorte 1	mild	Agonist	2.64	844	1.66	4.27	38.74	0.47	5.69
55	$PD-0041_pDC_D1$	Cohorte 1	mild	Mock	5.73	1136	1.14	3.52	6.34	0.53	7.39
1	$PD-0041_pDC_D2$	Cohorte 1	mild	SARS	5.83	1494	0.00	8.10	8.10	0.47	4.4
89	$PD-0041_pDC_D3$	Cohorte 1	mild	Agonist	3.57	1317	0.68	4.71	68.34	0.99	5.7'
60	$PS-0029_pDC_A1$	Cohorte 6	mild	Mock	1.97	707	10.89	9.48	15.84	1.70	8.63
50	$PS-0029_pDC_A2$	Cohorte 6	mild	SARS	2.90	762	1.71	13.12	19.03	1.71	8.5
138	$PS-0029_pDC_A3$	Cohorte 6	mild	Agonist	5.74	1185	0.34	15.78	67.93	2.70	14.7'
97	$PS-0029_pDC_C1$	Cohorte 6	mild	Mock	2.20	764	3.40	3.27	17.93	1.83	9.69
31	$PS-0029_pDC_C2$	Cohorte 6	mild	SARS	3.03	892	1.12	4.82	16.70	2.02	10.0
52	PS-0029_pDC_C3	Cohorte 6	mild	Agonist	3.72	1499	0.07	20.01	74.52	2.74	11.4
117	PS-0029_pDC_E1	Cohorte 6	mild	Mock	3.40	856	3.97	4.44	13.90	3.86	8.53
43	$PS-0029_pDC_E2$	Cohorte 6	mild	SARS	4.31	1026	2.14	3.31	13.74	2.05	9.00
46	PS-0029_pDC_E3	Cohorte 6	mild	Agonist	5.59	1789	0.39	18.84	70.82	1.29	9.50
74	PS-0029_pDC_F1	Cohorte 6	mild	Mock	3.91	1593	5.08	4.52	18.08	4.02	12.8
95	PS-0029_pDC_F2	Cohorte 6	mild	SARS	4.61	1831	3.50	7.10	13.54	2.95	9.6

	Patient	Cohorte	Status	Activation	pDCs	nCells	IFNl	CD83	PDL1	IFNa	CD8
91	PS-0029_pDC_F3	Cohorte 6	mild	Agonist	4.24	2125	0.14	12.19	62.12	0.99	10.10
10	RESU_pDC_H1	Cohorte 6	severe	Mock	1.23	333	11.71	3.00	30.33	4.50	19.53
80	RESU_pDC_H2	Cohorte 6	severe	SARS	0.96	317	9.78	3.79	40.06	5.05	30.60
87	RESU_pDC_I1	Cohorte 6	severe	Mock	0.70	330	9.39	3.64	45.76	8.18	35.48
130	$RESU_pDC_I2$	Cohorte 6	severe	SARS	0.99	273	14.65	2.20	36.63	5.86	32.23



Figure 2: Cohorts and Markers

GradientBoosting

```
Index(['IFN1', 'CD83', 'PDL1', 'IFNa', 'CD80', 'Patient', 'Cohorte',
       'Activation', 'Severity', 'Status', 'perc_pDCs'],
      dtype='object')
         219346.000000
count
             0.577266
mean
std
              0.715441
              0.000000
min
25%
              0.000000
50%
              0.000000
75%
              1.000000
              2.000000
max
Name: Severity, dtype: float64
/home/dcluet/.local/share/r-miniconda/envs/r-reticulate/lib/python3.8/site-packages/sklearn/metrics/_cl
  warnings.warn("y_pred contains classes not in y_true")
/home/dcluet/.local/share/r-miniconda/envs/r-reticulate/lib/python3.8/site-packages/sklearn/metrics/_cl
  warnings.warn("y_pred contains classes not in y_true")
/home/dcluet/.local/share/r-miniconda/envs/r-reticulate/lib/python3.8/site-packages/sklearn/metrics/_cl
  warnings.warn("y_pred contains classes not in y_true")
{'fit_time': array([16.49790716, 17.45981765, 13.51742291, 17.6325624, 17.32238173,
       16.75848651, 19.59194899, 19.82147479]), 'score_time': array([0.11953616, 0.09111857, 0.18471885
       0.09295154, 0.02360559, 0.01121163]), 'test_accuracy': array([0.5097744 , 0.63801592, 0.48242422
       0.46278536, 0.8987679, 0.97243859]), 'test_balanced_accuracy': array([0.34892726, 0.34258867, 0
       0.34018951, 0.8987679, 0.97243859]), 'test_neg_mean_absolute_error': array([-0.71004638, -0.383
       -0.57659057, -0.1012321 , -0.02756141])}
   accuracy balanced accuracy mean absolute error
0 0.509774
                     0.348927
                                          0.710046
1 0.638016
                     0.342589
                                           0.383666
2 0.482424
                     0.387522
                                          0.693469
3 0.493294
                     0.494562
                                          0.506904
4 0.571277
                     0.344187
                                          0.437998
5 0.462785
                     0.340190
                                          0.576591
6 0.898768
                     0.898768
                                          0.101232
7 0.972439
                     0.972439
                                          0.027561
Pipeline(steps=[('preprocessor',
                 ColumnTransformer(remainder='passthrough', sparse_threshold=0,
                                   transformers=[('cat_preprocessor',
                                                  OrdinalEncoder(handle_unknown='use_encoded_value',
                                                                 unknown_value=-1),
                                                  ['Activation'])])),
                ('classifier', GradientBoostingClassifier(random_state=666))])
```

The test accuracy using a Pipeline is 0.562

features	importance
IFNl	0.3555306
CD83	0.2197104
PDL1	0.0804040
IFNa	0.2062035
CD80	0.0266727
Activation	0.1114788

Linear Regression


TENI	anaa	DDI 4	TPM-
IFN1	CD83	PDL1	IFNa
Min. :0.000	Min. :0.00000	Min. :0.0000	Min. :0.00000
1st Qu.:0.000	1st Qu.:0.00000	1st Qu.:0.0000	1st Qu.:0.00000
Median :0.000	Median :0.00000	Median :0.0000	Median :0.00000
Mean :0.102	Mean :0.07435	Mean :0.2532	Mean :0.01763
3rd Qu.:0.000	3rd Qu.:0.00000	3rd Qu.:1.0000	3rd Qu.:0.00000
Max. :1.000	Max. :1.00000	Max. :1.0000	Max. :1.00000
CD80	Patient	Cohorte	Activation
Min. :0.00000	Length:219346	Length:219346	
1st Qu.:0.00000	Class :characte		<u> </u>
Median :0.00000	Mode :characte	er Mode :charac	ter SARS :77540
Mean :0.06908			
3rd Qu.:0.00000			
Max. :1.00000			
Severity	Status	perc_pDCs	
Min. :0.0000	healthy:122098	Min. : 0.700	
1st Qu.:0.0000	mild : 67875	1st Qu.: 4.150	
Median :0.0000	severe : 29373	Median : 7.730	
Mean :0.5773		Mean : 8.254	
3rd Qu.:1.0000		3rd Qu.:10.700	
Max. :2.0000		Max. :28.000	
IFN1	CD83	PDL1	IFNa
Min. :0.0000	Min. :0.00000	Min. :0.0000	Min. :0.00000
1st Qu.:0.0000	1st Qu.:0.00000	1st Qu.:0.0000	1st Qu.:0.00000
Median :0.0000	Median :0.00000	Median :0.0000	Median :0.00000
Mean :0.1015	Mean :0.07404	Mean :0.2534	Mean :0.01717
3rd Qu.:0.0000	3rd Qu.:0.00000	3rd Qu.:1.0000	3rd Qu.:0.00000
Max. :1.0000	Max. :1.00000	Max. :1.0000	Max. :1.00000
CD80	Patient	Cohorte	Activation
Min. :0.00000	Length:153544	Length:153544	
1st Qu.:0.00000	Class :characte	er Class:charac	ter Agonist:57682
Median :0.00000	Mode :characte	er Mode :charac	ter SARS :54221
Mean :0.06986			
3rd Qu.:0.00000			
Max. :1.00000			
Severity	Status	perc_pDCs	
Min. :0.0000	healthy:85469	Min. : 0.700	
1st Qu.:0.0000	mild :47513	1st Qu.: 4.150	
Median :0.0000	severe :20562	Median : 7.730	
Mean :0.5773		Mean : 8.251	
3rd Qu.:1.0000		3rd Qu.:10.700	
Max. :2.0000		Max. :28.000	
IFN1	CD83	PDL1	IFNa
Min. :0.0000	Min. :0.00000	Min. :0.0000	Min. :0.00000
1st Qu.:0.0000	1st Qu.:0.00000	1st Qu.:0.0000	1st Qu.:0.00000
Median :0.0000	Median :0.00000	Median :0.0000	Median :0.00000
Mean :0.1032	Mean :0.07509	Mean :0.2528	Mean :0.01871
3rd Qu.:0.0000	3rd Qu.:0.00000	3rd Qu.:1.0000	3rd Qu.:0.00000
Max. :1.0000	Max. :1.00000	Max. :1.0000	Max. :1.00000
CD80	Patient	Cohorte	Activation


Min. :0.00000 Length:65802 Length:65802 Mock :17709 1st Qu.:0.00000 Class :character Class :character Agonist:24774 Median :0.00000 Mode :character Mode :character SARS :23319

Mean :0.06725 3rd Qu.:0.00000

:1.00000 Max.

Severity perc_pDCs Status :0.0000 healthy:36629 Min. : 0.700 Min. 1st Qu.:0.0000 mild :20362 1st Qu.: 4.150 Median :0.0000 severe : 8811 Median : 7.730Mean :0.5772 Mean : 8.261 3rd Qu.:1.0000 3rd Qu.:10.700 Max. :2.0000 Max. :28.000





Confusion Matrix and Statistics

Reference

Prediction healthy mild severe healthy 27109 9531 2384 mild 5274 4304 539 severe 53086 33678 17639

Overall Statistics

Accuracy : 0.3195

95% CI : (0.3171, 0.3218)

No Information Rate : 0.5566

P-Value [Acc > NIR] : 1

Kappa : 0.0891

Mcnemar's Test P-Value : <2e-16

Statistics by Class:

	Class:	healthy	Class: mild	Class:	severe
Sensitivity		0.3172	0.09059		0.8578
Specificity		0.8250	0.94518		0.3476
Pos Pred Value		0.6947	0.42542		0.1690
Neg Pred Value		0.4904	0.69874		0.9405

Prevalence	0.5566	0.30944	0.1339
Detection Rate	0.1766	0.02803	0.1149
Detection Prevalence	0.2542	0.06589	0.6800
Balanced Accuracy	0.5711	0.51788	0.6027

Confusion Matrix and Statistics

Reference

Prediction healthy mild severe healthy 11663 4182 1009 mild 2307 1859 263 severe 22659 14321 7539

Overall Statistics

Accuracy : 0.3201

95% CI : (0.3165, 0.3236)

No Information Rate : 0.5567

P-Value [Acc > NIR] : 1

Kappa : 0.0886

Mcnemar's Test P-Value : <2e-16

Statistics by Class:

	Class:	healthy	Class: mild	Class:	severe
Sensitivity		0.3184	0.09130		0.8556
Specificity		0.8221	0.94344		0.3511
Pos Pred Value		0.6920	0.41973		0.1693
Neg Pred Value		0.4899	0.69852		0.9402
Prevalence		0.5567	0.30944		0.1339
Detection Rate		0.1772	0.02825		0.1146
Detection Prevalence		0.2561	0.06731		0.6766
Balanced Accuracy		0.5702	0.51737		0.6034

Mutinomial regressions Coefficients

(Intercept) IFN1 CD83 PDL1 IFNa CD80 mild -0.1019738 -0.6249131 0.6529562 -0.6358566 0.07556378 0.6713043 severe 0.1492162 -1.5020310 -0.5225393 -1.1345213 -0.36784565 1.1584182 ActivationAgonist ActivationSARS

mild 0.5724939 0.02573557 severe 0.4986338 -0.12941995